With the HT-100, ANAVIA has developed the most advanced unmanned aerial vehicle (UAV) system in the world. An unmanned helicopter for up to 65 kg of payload and 240 minutes of flight time. It’s the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy (DMD), today reported that ...
Scale model of HT-100 displayed at IDEX 2025. (Janes/Amit Kalra) Anavia, an Edge Group entity, exhibited a scale model of the naval version of its HT-100 unmanned aerial vehicle (UAV) at the ...
EDGE’s Swiss subsidiary Anavia has demonstrated what its parent company describes as a “complex flight profile” with an HT-100 unmanned air vehicle for the Brazilian armed forces and police. Recently ...
Preliminary Clinical Data from Ongoing Phase 1b/2a Clinical Program Presented at New Directions in Biology and Disease of Skeletal Muscle 6th Biennial Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
Dubai, United Arab Emirates: EDGE Group entity, Abu Dhabi Ship Building (ADSB), has adopted several HT-100 multi-role unmanned performance helicopters for integration onto the vessels of one of its ...
Halo Therapeutics announced that the FDA has granted orphan drug designation for HT-100 (halofuginone) for Duchenne muscular dystrophy (DMD). Plans to initiate a Phase 2 trial in 2012 are underway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results